Next-Generation Multi-Signal Fluorescent Probe System for Enhanced Tumor Diagnosis
Legal Citation
Summary of the Inventive Concept
A revolutionary multi-signal fluorescent probe system that integrates nanoscale sensor arrays, machine learning algorithms, and microfluidic devices for real-time, high-throughput detection of multiple biomarkers, enabling early and accurate tumor diagnosis, treatment monitoring, and personalized medicine.
Background and Problem Solved
The original patent disclosed a multi-signal fluorescent probe for early diagnosis of tumors. However, it has limitations in terms of sensitivity, specificity, and real-time detection capabilities. The next-generation system addresses these limitations by incorporating advanced nanotechnology, artificial intelligence, and microfluidics to provide a more accurate, efficient, and personalized approach to tumor diagnosis and treatment.
Detailed Description of the Inventive Concept
The next-generation multi-signal fluorescent probe system consists of a nanoscale sensor array designed to detect simultaneous changes in multiple biomarkers, enabling early detection of tumor recurrence. The system is integrated with a machine learning algorithm that generates personalized biomarker profiles for patients based on medical history and genetic data. Additionally, the system incorporates a microfluidic device for high-throughput screening of tumor cells, allowing for real-time monitoring of tumor progression and treatment efficacy. The system's advanced capabilities enable clinicians to make data-driven decisions, improving patient outcomes and reducing healthcare costs.
Novelty and Inventive Step
The next-generation system's combination of nanoscale sensor arrays, machine learning algorithms, and microfluidic devices for real-time, high-throughput detection of multiple biomarkers is a novel and non-obvious advancement over the original patent. The system's ability to generate personalized biomarker profiles, monitor tumor progression in real-time, and enable data-driven decision-making represents a significant inventive step in the field of tumor diagnosis and treatment.
Alternative Embodiments and Variations
Alternative embodiments of the next-generation system could include the use of different nanomaterials, sensor configurations, or machine learning algorithms. Variations could also include the integration of additional diagnostic tools, such as imaging modalities or genomic analysis, to provide a more comprehensive understanding of tumor biology and treatment response.
Potential Commercial Applications and Market
The next-generation multi-signal fluorescent probe system has significant commercial potential in the fields of oncology, diagnostics, and personalized medicine. The system could be marketed to hospitals, research institutions, and pharmaceutical companies, with potential applications in clinical trials, companion diagnostics, and precision medicine.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K49/003 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biomedical diagnostics, fluorescence-based molecular detection, and advanced medical imaging technologies with expertise in nanoscale sensing, machine learning applications in medical diagnostics, and microfluidic systems
Person of Ordinary Skill (PHOSITA) Profile
A professional with advanced degrees in bioengineering, biochemistry, or medical technology, possessing expertise in fluorescent probe design, molecular detection techniques, and interdisciplinary diagnostic technology integration
Obviousness Rationale
A PHOSITA would recognize that the published technical disclosure represents a predictable extension of the source patent's fluorescent probe technology by integrating emerging diagnostic technologies like machine learning and microfluidic systems. The core fluorescence-based diagnostic approach remains consistent, with the novel elements representing standard technological augmentations in medical diagnostic platforms. The systematic combination of nanoscale sensing, predictive analytics, and high-throughput screening represents an incremental rather than transformative advancement in tumor diagnostic methodologies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,644 |
|---|---|
| Title | Multi-signal fluorescent probe for early diagnosis of tumors, and preparation and use thereof |
| Assignee(s) | Hunan Normal University, Hunan Cancer Hospital |